恒瑞医药再涨超5% 收到国家药监局签发关于HRS-7172片的《药物临床试验批准通知书》

Core Viewpoint - Heng Rui Medicine (600276)(01276) has seen a stock price increase of over 5%, currently trading at 84.9 HKD with a transaction volume of 153 million HKD, following the approval of a clinical trial for its new anti-tumor drug HRS-7172 by the National Medical Products Administration [1] Group 1: Company Developments - The company announced on September 2 that it received the clinical trial approval notice for HRS-7172 tablets from the National Medical Products Administration [1] - HRS-7172 is a new small molecule inhibitor for anti-tumor treatment developed independently by the company [1] - Currently, there are no similar drugs approved for market release domestically or internationally [1] - The total research and development investment for the HRS-7172 project has reached approximately 28.41 million CNY [1]